Clinical results of the application of the combination of bortezomibum and dexamethasone in the first-line therapy of multiple myelomas
SUMMARY In this paper, the efficacy of the VD scheme use in patients with newly diagnosed multiple myeloma for the period 20122017, in the department of hemoblastoses of Kazakh Institute of oncology and radiology was evaluated. The effectiveness of treatment was assessed after 4-6 cycles of VD. Objective: To evaluate the efficacy of the VD regimen (bortezomib + dexamethasone) in the first line of multiple myeloma therapy. Methods. The study included 40 patients with newly diagnosed MM who received treatment according to the VD scheme in the department of hemoblastoses of of Kazakh Institute of oncology and radiology from 2012 to 2017. The median age was 59 years (40-81 years). Results. Using the VD scheme in patients with newly diagnosed MM, the overall response rate was 75%. 40.6% of patients complete remission was achieved, in 16.6% of patients was very good partial remission, in 43.3% of patients - partial remission. Progression of the disease on the therapy background according to the VD scheme occurred in 25% of patients. The median time to achieve complete remission was 4 months. The overall survival of patients was 28 months. The transferability of treatment according to the VD scheme was satisfactory regardless of the age of the patients. Among the side effects anemia (42.5), peripheral neuropathy (35.5%), asthenic syndrome (25%), dyspepsia syndrome (22.5%) were observed. The conclusion. The VD scheme has a manageable and predictable toxic profile, is effective and plays an important role in MM therapy as a first line, and leads to a significant increase in the overall survival of patients compared to treatment methods without the use of proteasome inhibitors.